RISK WATCHYahoo Finance • 7h ago
Johnson & Johnson stock falls despite strong earnings as investors focus on medtech unitYahoo Finance report covering Johnson & Johnson (JNJ) market action, institutional positioning, and fundamental catalysts.
Why JNJ Stock slipped -0.73% Today — RQD Quant Desk Flash
$273.20 -0.73% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $273.50
Johnson & Johnson (JNJ) earns a Roarable Rating of A- (Buy) with 82/100 RQD Confidence. High-quality cash engine (68% profit margin, 26% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
ROARABLE A- • BUY
Cap $662.49B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on JNJ Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is JNJ stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Johnson & Johnson (NYSE: JNJ) is rated A- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 82/100 at a spot price of $273.20 (-0.73% 1D, market cap $662.49B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, JNJ ranks #8 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does JNJ compare to ABBV and MRK in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), JNJ carries a Roarable A- (82/100 RQD), trailing P/E of 24.7x, gross margin of 67.9%, and ROIC of 25.5%. By comparison, ABBV (AbbVie Inc.) holds a A- grade (81/100 RQD, P/E 121.6x, ROIC 29.0%, cap $513.86B) and MRK (Merck & Company Inc.) posts a B grade (75/100 RQD, P/E 19.8x, ROIC 20.7%, cap $361.02B). Among the 5-stock peer group, MRK leads on earnings multiple (19.8x) while ABBV leads on capital efficiency (29.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for JNJ?
▼
Per JNJ's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-28, CIK 0000200406), Johnson & Johnson generated $94.19B in revenue (+6.0% YoY), $26.80B in net income, and $19.70B in free cash flow against $199.21B in total assets and $39.44B in total debt. Key quantitative strengths: Strong cash generator (68% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $273.50 (+0.11%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 15/20 (B) • 20.9% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 82/100 (A-) historically ranked in the Top 7% of excess returns over the next 90 days (+8.6% avg 90D alpha vs SPY • 71.9% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERBUY • A-
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw B+ · Rk A-
Each axis scored 0–20
12M PRICE TARGET CONE+10.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for JNJ)Realized 20D OHLCV Swing Band: ±5%
Deterministic 5-Pillar Attribution (82/100 Composite)
🔍 WHY JNJ SCORES 82/100 (A-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+18/20 pts (22% of score)
20D Institutional Volume Accumulation (±5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (22% of score)
Altman Z-Score 5.59 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution15/20 pts (-5 pt drag)
Cannibal Buyback (-2.08% YoY Shares) & executive Form 4 sales trim 5 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade B+$248.61+4.3% Next Q
74
Q2 (-2Q)Grade B+$259.36+3.6% Next Q
77
Q3 (-1Q)Grade A-$268.73+1.7% Next Q
79
CurrentGrade A-$273.20+8.6% Hist 90D α
82
Trajectory: B+ (74) → A- (82)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the JNJ Bull Thesis Could Fail
Even with a 82/100 (A-) score, JNJ faces multiple-compression risk if 24.7x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Broader market pullbacks can still drag down strong stocks in the short run.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 65.4% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($265.74) or 200D SMA ($247.55) invalidates the momentum regime and cuts Target Base ($302.71) toward Bear Floor ($224.02).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $JNJ• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “JNJ Beats Next Quarter EPS Consensus (Dec 27, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why JNJ Stock slipped -0.73% Today — RQD Quant Desk Flash
Johnson & Johnson (JNJ) slipped -0.73% to $273.20, trading at 91% of its 52-week range ($185.12 – $282.02). High-quality cash engine (68% profit margin, 26% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 91% of its 52-week range ($185.12 – $282.02) with RSI-14 at 62.1 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±5% around $273.20 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable A- (Buy) backed by 67.9% gross margin and $19.7B annual free cash flow.
Live JNJ Headlines & Catalysts
RISK WATCHCNBC • 10h ago
J&J posts weak medical device sales, shares fallCNBC report covering Johnson & Johnson (JNJ) market action, institutional positioning, and fundamental catalysts.
RISK WATCHThe Motley Fool • 13h ago
Why Johnson & Johnson Stock Dropped TodayThe Motley Fool report covering Johnson & Johnson (JNJ) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBarron's • 16h ago
Johnson &Johnson Stock Earnings: Can a Spinoff Fix Its Medtech ProblemBarron's report covering Johnson & Johnson (JNJ) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETrefis • 19h ago
The Open Question Under Johnson & Johnson Stock’s PriceTrefis report covering Johnson & Johnson (JNJ) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvestopedia • 22h ago
Here’s How Much Johnson & Johnson Stock Is Expected to Move After EarningsInvestopedia report covering Johnson & Johnson (JNJ) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo Finance • 1d ago
Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to NoteYahoo Finance report covering Johnson & Johnson (JNJ) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo Finance • 1d ago
Johnson & Johnson Stock Has Surged 44%, Can Its Growth Justify the Valuation?Yahoo Finance report covering Johnson & Johnson (JNJ) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 8h ago
How well is J&J’s incubator model working?After incubating about 1,200 companies, the pharma giant is putting less emphasis on physical lab space — and taking a more targeted approach to new science.
CATALYSTYahoo • 9h ago
2 Safe S&P 500 Healthcare Dividend Stocks Boomers Can Buy and Hold ForeverHealthcare bills arrive whether the economy cooperates or not, and two S&P 500 drugmakers have quietly turned that reality into decades of unbroken dividend raises. The question is whether their cash flow holds up under
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (JNJ Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
JNJ // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +21.86%📐 HORIZONTAL RANGE
2026-11-02O $271.0H $275.2L $271.0C $273.2VOL 6.02M
RES: $282.1SUP: $243.6SMA50: $265.7SMA200: $247.6
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
JNJ Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
18.4%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on JNJ today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for JNJ. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for JNJ today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (JNJ)
Health Care Rank #8 of 1016
⚔️ ABBV vs JNJ Full Matrix →
1. Head-to-Head Health Care Peer Comparison (JNJ vs. ABBV, MRK, NVS, AZN)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Johnson & Johnson (JNJ) ranks #8 by composite RQD confidence (82/100, grade A-) and #2 by equity capitalization ($662.49B). Within this direct 5-issuer industry benchmark cohort, MRK leads on earnings valuation at 19.8x trailing P/E, while ABBV leads on capital efficiency and profitability with 29.0% ROIC and 70.2% gross margin. JNJ currently leads its immediate peer cohort in composite quantitative strength at 82/100 (A-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| JNJ
ACTIVE
Johnson & Johnson | A- | 82/100 | 24.7x | 67.9% | 25.5% | -0.73% | $662.49B | Benchmark Subject |
| ABBV AbbVie Inc. | A- | 81/100 | 121.6x | 70.2% | 29.0% | +1.41% | $513.86B | /abbv-vs-jnj → |
| MRK Merck & Company Inc. | B | 75/100 | 19.8x | 74.8% | 20.7% | +2.18% | $361.02B | /mrk-vs-jnj → |
| NVS Novartis AG | C+ | 66/100 | 32.8x | — | 9.9% | -0.19% | $307.40B | /nvs-vs-jnj → |
| AZN AstraZeneca PLC | C | 62/100 | 32.8x | — | 9.9% | +7.02% | $270.45B | /azn-vs-jnj → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-28 • CIK 0000200406In its most recent audited fiscal period (FY2025, filed 2025-12-28), Johnson & Johnson (JNJ) reported GAAP revenue of $94.19B (+6.0% vs. FY2024 revenue of $88.82B , and +10.6% cumulative change since FY2023) , GAAP net income of $26.80B, operating cash flow of $24.53B, and free cash flow of $19.70B (-0.7% YoY). On the balance sheet, JNJ closed FY2025 with $199.21B in total assets against $39.44B in total debt (Altman Z-Score: 5.59, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-28 | $94.19B | $26.80B | $24.53B | $19.70B | $199.21B | $39.44B |
| FY2024 (FY) | 2024-12-29 | $88.82B | $14.07B | $24.27B | $19.84B | $180.10B | $30.65B |
| FY2023 (FY) | 2023-12-31 | $85.16B | $35.15B | $22.79B | $18.96B | $364.37B | $85.26B |
3. JNJ Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs JNJ stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Johnson & Johnson (NYSE: JNJ) is rated A- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 82/100 at a spot price of $273.20 (-0.73% 1D, market cap $662.49B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, JNJ ranks #8 in composite RQD confidence.
How does JNJ compare to ABBV and MRK in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), JNJ carries a Roarable A- (82/100 RQD), trailing P/E of 24.7x, gross margin of 67.9%, and ROIC of 25.5%. By comparison, ABBV (AbbVie Inc.) holds a A- grade (81/100 RQD, P/E 121.6x, ROIC 29.0%, cap $513.86B) and MRK (Merck & Company Inc.) posts a B grade (75/100 RQD, P/E 19.8x, ROIC 20.7%, cap $361.02B). Among the 5-stock peer group, MRK leads on earnings multiple (19.8x) while ABBV leads on capital efficiency (29.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for JNJ?
Per JNJ's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-28, CIK 0000200406), Johnson & Johnson generated $94.19B in revenue (+6.0% YoY), $26.80B in net income, and $19.70B in free cash flow against $199.21B in total assets and $39.44B in total debt. Key quantitative strengths: Strong cash generator (68% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is JNJ trading relative to its 50-day, 200-day, and 52-week technical levels?
JNJ last traded at $273.20 (-0.73% on volume of 8,969,509 shares), positioning the stock +2.81% above its 50-day simple moving average ($265.74) and +10.36% above its 200-day simple moving average ($247.55). Across its 52-week range of $185.12 to $282.02, JNJ sits at the 90.9% percentile with a 14-day RSI of 62.1 (BULLISH MOMENTUM) and an implied next-earnings move of ±5.0% ($259.54 to $286.86).
JNJ Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is JNJ stock moving today?
Why JNJ Stock slipped -0.73% Today — RQD Quant Desk Flash. High-quality cash engine (68% profit margin, 26% return on capital) with steady institutional support.
ROARABLE RATING BRIEF • RQD 82/100 (A-)
✓ STAGE-C NUMBER FIREWALL VERIFIED
JNJ — Johnson & Johnson: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:08:46Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, JNJ scores 82 out of 100, a letter grade of A-, with the verdict label "Roarable Buy — Superior Risk/Reward." The five pillars are: Fundamental Cash Engine at 15/20 (ROIC 25.5%; FCF yield 2.97%); Whale 13F Flow at 18/20 (institutional accumulation and options positioning); Insider Conviction at 15/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 16/20 (Beta 1.08; sector sensitivity); and Forensic Balance Sheet at 18/20 (Altman Z 5.59; Piotroski F 8/9; Debt/Equity 0.48).
For a prospective investor, the strongest pillars are Whale 13F Flow and Forensic Balance Sheet, both at 18/20. The balance-sheet pillar suggests financial-distress risk is low on the metrics cited. The weakest-scoring pillars, Fundamental Cash Engine and Insider Conviction at 15/20 each, are the areas where the case is comparatively less complete. The free-cash-flow yield of 2.97% is a valuation tradeoff: it implies a meaningful premium is being paid for cash generation relative to the price, which the verdict label weighs against the quality metrics. Macro sensitivity is moderate, with a beta of 1.08 indicating slightly higher market sensitivity than the broad market. This brief is analytical and educational and does not constitute personalized financial advice.
Snapshot
Recent Catalysts & News Wire Analysis
The news wire contains six headlines, all relating to Johnson & Johnson (JNJ). Three are flagged RED / RISK WATCH: a Yahoo Finance report that the stock fell despite strong earnings as investors focused on the medtech unit; a CNBC report on weak medical device sales with shares falling; and a Motley Fool report on the day's drop. Three are flagged YELLOW / MARKET WIRE: a Barron's piece asking whether a spinoff can fix the medtech problem; a Trefis piece on the open question under the stock price; and an Investopedia piece on expected post-earnings move. The recurring theme across the wire is medtech unit weakness, with a spinoff discussed as a possible remedy. The Butterfly Supply-Chain Graph reports no proprietary signals and no links.
Open Questions
- What is the segment-level revenue and profit breakdown, particularly for the medtech unit referenced in the news wire?
- What is the status and timeline of the spinoff discussed in the Barron's headline, and what would it change for the consolidated financials?
- Why are EPS and FY 2023 cash not reported in the financial data, and how would per-share results compare with the net-income trend?
- What specific institutional, insider, and Congressional transactions underpin the 18/20 whale and 15/20 insider pillar scores?
- What analyst consensus, price targets, and rating distribution apply to JNJ?
JNJ Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Johnson & Johnson (JNJ) • Click "Debate This Headline" to argue it in the Roar Pit below
🔴 RISK WATCH Yahoo Finance • 7h ago
Johnson & Johnson stock falls despite strong earnings as investors focus on medtech unit Yahoo Finance report covering Johnson & Johnson (JNJ) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH CNBC • 10h ago
J&J posts weak medical device sales, shares fall CNBC report covering Johnson & Johnson (JNJ) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH The Motley Fool • 13h ago
Why Johnson & Johnson Stock Dropped Today The Motley Fool report covering Johnson & Johnson (JNJ) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Barron's • 16h ago
Johnson &Johnson Stock Earnings: Can a Spinoff Fix Its Medtech Problem Barron's report covering Johnson & Johnson (JNJ) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Trefis • 19h ago
The Open Question Under Johnson & Johnson Stock’s Price Trefis report covering Johnson & Johnson (JNJ) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investopedia • 22h ago
Here’s How Much Johnson & Johnson Stock Is Expected to Move After Earnings Investopedia report covering Johnson & Johnson (JNJ) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 1d ago
Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note Yahoo Finance report covering Johnson & Johnson (JNJ) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 1d ago
Johnson & Johnson Stock Has Surged 44%, Can Its Growth Justify the Valuation? Yahoo Finance report covering Johnson & Johnson (JNJ) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
JNJ Bull vs. Bear Conversation Board — What's Your Call at $273.20?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON JNJ 🐻 33% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH
🎯 Target: $324.74 (+18.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is JNJ (A- • RQD 82/100) a Buy at $275.20?
Welcome to the JNJ (Johnson & Johnson) Roar Pit. Current RQD Composite is 82/100 (Roarable Buy — Superior Risk/Reward) in Biotechnology: Pharmaceutical Preparations. Bulls point to capital efficiency (25.5% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $222.91 (-19.0%)
Spot @ $275.20 Pump the brakes on JNJ — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on JNJ, but look at what you are paying: 24.7x trailing P/E with 67.9% gross margins. Unless Johnson & Johnson expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
QU QuantViper Verified K Arena Trader 🐂 BULLISH
🎯 Target: $335.74 (+22.0%)
Spot @ $275.20 JNJ cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on JNJ, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $275.20 (52-wk range $185.12 - $282.02), any beat on forward guidance forces shorts and underweight funds to chase.